Recent reports uncovered the potential of liquid biopsies in monitoring MRD by screening EVs isolated in MM remission patients for MM biomarkers such as CD56, CD117, CD27, CD55, CD59, PD-L1 and CD38 (188, 189). This evidence concerns the gene NCAM1 and Miyoshi myopathy.